Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218744 | 0.96 | MEN1 (0.75) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL27182266 | 0.92 | MEN1 (0.69) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL27182343 | 0.92 | MEN1 (0.69) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL27182275 | 0.92 | MEN1 (0.69) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL1578099 | 0.90 | MAPT (0.74) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL2217583 | 0.89 | KMT2A (1.00) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL1578309 | 0.89 | MEN1 (0.72) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL2219069 | 0.89 | LMNA (0.76) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL15693741 | 0.88 | KMT2A (0.77) | KMT2AMEN1L3MBTL1MAPTLMNA | |
| SCHEMBL2217132 | 0.88 | MAPT (0.74) | KMT2AMEN1L3MBTL1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116042209-A | Preparation method and application of mesoporous silicon-based aggregation-induced emission material | 中国科学院上海硅酸盐研究所 | 2023-05-02 | — | — | CN | disclosed |
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| CN-103983627-A | Pyridopyrimidine compounds as anti-tubercular agents | PASTEUR INSTITUT KOREA | 2014-08-13 | — | — | CN | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| CN-102105470-B | Pyridopyrimidine compounds as antitubercular agents | PASTEUR INSTITUT KOREA | 2014-06-04 | — | — | CN | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | KMT2A 4781/4885MEN1 3685/4885L3MBTL1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.